Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
163.51B
Market cap163.51B
Price-Earnings ratio
17.69
Price-Earnings ratio17.69
Dividend yield
2.48%
Dividend yield2.48%
Average volume
7.27M
Average volume7.27M
High today
$132.95
High today$132.95
Low today
$129.20
Low today$129.20
Open price
$129.60
Open price$129.60
Volume
4.47M
Volume4.47M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$107.75
52 Week low$107.75

Stock Snapshot

The current Gilead Sciences(GILD) stock price is $131.70, with a market capitalization of 163.51B. The stock trades at a price-to-earnings (P/E) ratio of 17.69 and offers a dividend yield of 2.48%.

On 2026-07-15, Gilead Sciences(GILD) stock moved within a range of $129.20 to $132.95. With shares now at $131.70, the stock is trading +1.9% above its intraday low and -0.9% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 4.47M, versus its average volume of 7.27M.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $107.75.

GILD News

Simply Wall St 19h
Should Gilead’s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences Investors?

In its latest quarter, Gilead Sciences reported past revenues of US$6.96 billion, a 4.4% year-on-year increase that exceeded analysts’ expectations by 1.5% but...

Should Gilead’s Revenue Beat but Softer EPS Outlook Require Action From Gilead Sciences Investors?
Nasdaq 3d
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Key Points Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acquisition spree this past spring. Its stock spor...

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
TipRanks 5d
Gilead Expands Oncology Ambitions With New Denikitug Trial in Tough GI Cancers

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for...

Analyst ratings

83%

of 29 ratings
Buy
82.8%
Hold
17.2%
Sell
0%

More GILD News

TipRanks 5d
Gilead Targets Long-Acting HIV Control With New Injectable Study Versus Biktarvy

Gilead Sciences (GILD) announced an update on their ongoing clinical study. TipRanks has entered a new arena in the investing world, powering the index of an E...

TipRanks 6d
Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley

Morgan Stanley resumed coverage of Lakefront Biotherapeutics (LKFT) with an Equal Weight rating and $30 price target after the recent closing of the Ouro Medici...

Simply Wall St 6d
Gilead Stock Looks Below Fair Value But Earnings Already Look Priced In

Gilead Sciences stock has delivered a strong 5 year run, yet the valuation checks point to a mixed picture rather than a clear bargain or an obvious overvaluati...

Gilead Stock Looks Below Fair Value But Earnings Already Look Priced In

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.